Med Check: Aduhelm and Alzheimer's; BNC210 and Social Anxiety Disorder; COMP360 Psilocybin, Depression and More
T. D'Arrigo
Psychiatric News 2022 DOI: 10.1176/appi.pn.2022.1.2 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | News report Peer reviewed |
|---|---|
| Sample size | 1,800 |
| Population | Patients with Alzheimer's disease enrolled in the EMERGE and ENGAGE trials |
| Intervention | Aduhelm (aducanumab) |
| Topics | Anxiety Depression Psilocybin |
| Key points | In two phase 3 trials of aducanumab, reductions in plasma p-tau correlated with less cognitive and functional decline and with lower amyloid beta plaque burden in patients with Alzheimer's disease, according to Biogen and Eisai. An independent laboratory analyzed about 7,000 plasma samples from more than 1,800 patients. |
Abstract
Aduhelm Shows Promise for Alzheimer's DiseaseTwo phase 3 clinical trials of Aduhelm (aducanumab) showed a correlation between plasma p-tau reduction and less cognitive and functional decline in patients with Alzheimer's disease, Biogen and Esai announced last November. The accumulation of the protein tau inside neurons leads to neurofibrillary tangles—a pathological hallmark of Alzheimer's disease. The reductions in plasma p-tau were also correlated with a lowering of amyloid beta plaque, which is thought to play a role in the development of Alzheimer's. An independent laboratory analyzed approximately 7,000 plasma samples from more than 1,800 patients in the EMERGE and ENGAGE trials.